The target of a biotherapeutic can interfere in the detection of anti-drug antibodies (ADA). The presence of target in samples, especially targets .. Read more that exist as a multimer in solution, can cause false positives in the standard bridging assay format for ADA. Although not always straightforward, it can be addressed and mitigated in a properly designed immunoassay with sample pre-treatment. This webinar will give an overview of the different types of interferences, and current methodologies and approaches being utilized to resolve or reduce them.
- Share your Experience
More Events From The Organizer
- Sensor Summit Virtual24 Feb 2021Online